LT2792677T - Naujas junginys, tinkamas degeneracinių ir uždegiminių ligų gydymui - Google Patents

Naujas junginys, tinkamas degeneracinių ir uždegiminių ligų gydymui

Info

Publication number
LT2792677T
LT2792677T LTEP14175887.0T LT14175887T LT2792677T LT 2792677 T LT2792677 T LT 2792677T LT 14175887 T LT14175887 T LT 14175887T LT 2792677 T LT2792677 T LT 2792677T
Authority
LT
Lithuania
Prior art keywords
degenerative
treatment
inflammatory diseases
novel compound
compound useful
Prior art date
Application number
LTEP14175887.0T
Other languages
English (en)
Inventor
Javier Blanc
Christel Jeanne Marie Menet
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of LT2792677T publication Critical patent/LT2792677T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEP14175887.0T 2009-06-26 2010-06-25 Naujas junginys, tinkamas degeneracinių ir uždegiminių ligų gydymui LT2792677T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22068509P 2009-06-26 2009-06-26
US29818810P 2010-01-25 2010-01-25

Publications (1)

Publication Number Publication Date
LT2792677T true LT2792677T (lt) 2017-07-25

Family

ID=42340530

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14175887.0T LT2792677T (lt) 2009-06-26 2010-06-25 Naujas junginys, tinkamas degeneracinių ir uždegiminių ligų gydymui

Country Status (38)

Country Link
US (2) US8796457B2 (lt)
EP (2) EP2792677B1 (lt)
JP (1) JP5486084B2 (lt)
KR (1) KR101712561B1 (lt)
CN (1) CN102459261B (lt)
AR (1) AR077221A1 (lt)
AU (1) AU2010264635B2 (lt)
BR (1) BRPI1014759A2 (lt)
CA (1) CA2765988C (lt)
CL (1) CL2011003276A1 (lt)
CO (1) CO6491039A2 (lt)
CR (1) CR20110673A (lt)
CY (1) CY1119711T1 (lt)
DK (2) DK2792677T3 (lt)
DO (1) DOP2011000378A (lt)
EA (1) EA020111B1 (lt)
ES (2) ES2634325T3 (lt)
HK (2) HK1202537A1 (lt)
HR (2) HRP20141057T1 (lt)
HU (1) HUE034205T2 (lt)
IL (1) IL216618A (lt)
JO (1) JO3030B1 (lt)
LT (1) LT2792677T (lt)
MA (1) MA33447B1 (lt)
ME (1) ME01916B (lt)
MX (1) MX2011013451A (lt)
NZ (1) NZ596836A (lt)
PE (1) PE20120494A1 (lt)
PL (2) PL2792677T3 (lt)
PT (2) PT2792677T (lt)
RS (1) RS53617B1 (lt)
SG (1) SG177359A1 (lt)
SI (2) SI2445912T1 (lt)
SM (1) SMT201400169B (lt)
TW (1) TWI469981B (lt)
UY (1) UY32741A (lt)
WO (1) WO2010149771A1 (lt)
ZA (1) ZA201109502B (lt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP2696869B1 (en) 2011-04-12 2017-08-23 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
KR20200039028A (ko) * 2011-10-11 2020-04-14 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
UY34855A (es) * 2012-06-22 2014-01-31 Galapagos Nv Aminotriazolopiridina para usar el tratamiento de la inflamación y composiciones farmacéuticas de ella.
PE20161323A1 (es) 2013-09-05 2016-11-25 Hoffmann La Roche Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
WO2016165952A1 (en) * 2015-04-13 2016-10-20 Galapagos Nv Methods for the treatment of cardiovascular disorders
WO2018019222A1 (zh) 2016-07-26 2018-02-01 张文燕 作为jak抑制剂杂环化合物,该化合物的盐类及其治疗用途
WO2019149244A1 (zh) * 2018-01-31 2019-08-08 南京明德新药研发股份有限公司 Jak抑制剂及其应用
CN112955222A (zh) 2018-08-29 2021-06-11 里珍纳龙药品有限公司 用于治疗患有类风湿性关节炎的个体的方法和组合物
SG11202107735SA (en) 2019-01-31 2021-08-30 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
KR20240096817A (ko) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4058243B2 (ja) 1999-01-29 2008-03-05 中外製薬株式会社 軟骨形成促進剤およびインドリン−2−オン誘導体
EP1391211A1 (en) 2001-04-27 2004-02-25 Chugai Seiyaku Kabushiki Kaisha Chondrogenesis promoters
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
KR20050013562A (ko) * 2002-05-30 2005-02-04 버텍스 파마슈티칼스 인코포레이티드 Jak 및 cdk2 프로테인 키나아제의 억제제
ATE334131T1 (de) 2003-02-14 2006-08-15 Pfizer Prod Inc Triazolopyridine als entzündungshemmende verbindungen
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
ES2427046T3 (es) 2004-06-21 2013-10-28 Galapagos N.V. Métodos y medios para el tratamiento de la osteoartritis
JP2008509987A (ja) 2004-08-18 2008-04-03 ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー トリアゾロピリジン化合物
JP2008515874A (ja) 2004-10-07 2008-05-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌薬
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
AU2007291190A1 (en) * 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
CA2689514C (en) 2007-06-05 2015-09-29 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
US8263595B2 (en) 2007-08-31 2012-09-11 Merck Serono Sa Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20090217316A1 (en) * 2008-02-22 2009-08-27 Binita Gupta Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service
CN102131390A (zh) 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
AU2010254806C1 (en) 2009-06-05 2016-07-07 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物

Also Published As

Publication number Publication date
DOP2011000378A (es) 2012-02-15
TWI469981B (zh) 2015-01-21
DK2792677T3 (en) 2017-07-10
EP2445912A1 (en) 2012-05-02
CN102459261A (zh) 2012-05-16
CO6491039A2 (es) 2012-07-31
IL216618A0 (en) 2012-02-29
JP5486084B2 (ja) 2014-05-07
DK2445912T3 (da) 2014-11-10
ES2634325T3 (es) 2017-09-27
CR20110673A (es) 2012-02-09
PL2792677T3 (pl) 2017-09-29
ME01916B (me) 2015-05-20
SMT201400169B (it) 2015-01-15
NZ596836A (en) 2013-02-22
EP2792677A1 (en) 2014-10-22
AU2010264635B2 (en) 2015-05-07
SI2792677T1 (sl) 2017-08-31
PE20120494A1 (es) 2012-05-17
KR101712561B1 (ko) 2017-03-06
CY1119711T1 (el) 2018-06-27
IL216618A (en) 2014-09-30
BRPI1014759A2 (pt) 2016-04-19
EA201270076A1 (ru) 2012-08-30
CN102459261B (zh) 2014-11-05
HK1168098A1 (en) 2012-12-21
HRP20171024T1 (hr) 2017-10-06
MA33447B1 (fr) 2012-07-03
US9505754B2 (en) 2016-11-29
EA020111B1 (ru) 2014-08-29
AU2010264635A1 (en) 2011-12-22
RS53617B1 (en) 2015-04-30
TW201103937A (en) 2011-02-01
EP2792677B1 (en) 2017-04-26
US20150031671A1 (en) 2015-01-29
PL2445912T3 (pl) 2015-02-27
CA2765988C (en) 2017-08-29
US20100331359A1 (en) 2010-12-30
HK1202537A1 (en) 2015-10-02
MX2011013451A (es) 2012-04-30
ES2519170T3 (es) 2014-11-06
SI2445912T1 (sl) 2014-12-31
CA2765988A1 (en) 2010-12-29
EP2445912B1 (en) 2014-08-13
JP2012530767A (ja) 2012-12-06
HRP20141057T1 (en) 2015-03-13
US8796457B2 (en) 2014-08-05
HUE034205T2 (en) 2018-01-29
PT2445912E (pt) 2014-11-07
CL2011003276A1 (es) 2012-08-31
UY32741A (es) 2011-01-31
AR077221A1 (es) 2011-08-10
KR20120059487A (ko) 2012-06-08
SG177359A1 (en) 2012-02-28
PT2792677T (pt) 2017-07-06
ZA201109502B (en) 2012-09-26
JO3030B1 (ar) 2016-09-05
WO2010149771A1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
HRP20141057T1 (en) Novel compound useful for the treatment of degenerative and inflammatory diseases
HK1158635A1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases
HK1195311A1 (zh) 用於治療變性疾病和炎性疾病的新化合物
IL186749A0 (en) Dihydrothienopyrimidines for the treatment of inflammatory diseases
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
IL218852A0 (en) Compounds for the treatment of dyslipidemia and related diseases
HK1166305A1 (zh) 用於治療炎症的組合物及方法
EP2575824A4 (en) METHODS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
ZA201305970B (en) Arylosulfonami for the treatment of cns diseases
EP2350283A4 (en) COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY DISEASES OF THE CENTRAL NERVOUS SYSTEM
ZA201101821B (en) 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin deases
IL202502A (en) Cxcl11 for the treatment of inflammatory diseases
ZA201107562B (en) Compound for the treatment of tuberculosis